Dr. Kim Steegen

Kim Steegen is a clinical virologist and HIV drug resistance expert whose work centers on antiretroviral resistance in sub-Saharan Africa, particularly South Africa and Malawi. Affiliated with leading public health and laboratory networks in the region, Steegen contributes to national and regional HIV drug resistance surveillance, supporting evidence-based treatment policies in resource-limited settings.

Research focuses on phenotypic and genotypic resistance to integrase, NNRTI, and NRTI agents, including dolutegravir, doravirine, islatravir, and rilpivirine. Studies examine subtype C viruses, resistance pathways, and cross-resistance affecting long-acting therapies. This work bridges laboratory pseudovirus models, next-generation sequencing, and national program data to inform regimen selection and resistance management.

Additional contributions include evaluations of molecular diagnostics for SARS-CoV-2 and guidance on HIV drug resistance data sharing. Steegen’s scholarship strengthens laboratory capacity, advances implementation of resistance testing technologies, and shapes clinical and public health strategies to optimize treatment outcomes across low- and middle-income countries.